{"id":24548,"date":"2025-01-01T17:30:26","date_gmt":"2025-01-01T12:00:26","guid":{"rendered":"http:\/\/localhost\/current-affairs\/2025\/01\/01\/india-biotechnology-revolution-pioneering-innovation-and-sustainability\/"},"modified":"2026-10-24T06:41:32","modified_gmt":"2026-10-24T06:41:32","slug":"india-biotechnology-revolution-pioneering-innovation-and-sustainability","status":"publish","type":"post","link":"https:\/\/www.class24.study\/current-affairs\/india-biotechnology-revolution-pioneering-innovation-and-sustainability\/","title":{"rendered":"India Biotechnology Revolution: Pioneering Innovation and Sustainability"},"content":{"rendered":"<p><span style=\"font-weight: 400\">India&#8217;s biotechnology revolution is changing the way the country makes medicines, grows food, manages waste, and protects the environment. In just ten years, India&#8217;s bioeconomy has grown from about $10 billion in 2014 to over $130 billion in 2024, and the government now aims to take it to $300 billion by 2030. This growth is not a matter of numbers alone. It shows how science, innovation, and sustainability can work together to create jobs, improve public health, and support the vision of a Viksit Bharat by 2047.<\/span><\/p>\n<p><span style=\"font-weight: 400\">For students preparing for competitive exams or simply following current affairs, this topic is important because it connects policy, economy, health and environment in a single story.<\/span><\/p>\n<h2><b>What Is Biotechnology and the Bioeconomy?<\/b><\/h2>\n<p><span style=\"font-weight: 400\">Biotechnology means using living organisms, such as bacteria, yeast, plants, and human cells, or their parts to make useful products. Vaccines, antibiotics, biofuels, enzymes and bio-based plastics are all examples.<\/span><\/p>\n<p><span style=\"font-weight: 400\">The bioeconomy is the part of the economy that is built on such biological resources and processes. It includes biopharma, bio-agriculture, bio-industrial products, bio-energy and bio-services. When this economy also reuses waste as a raw material, it is called a circular bioeconomy, and this idea is at the heart of India&#8217;s new policy.<\/span><\/p>\n<h2><b>The BioE3 Policy: A Major Step Forward<\/b><\/h2>\n<p><span style=\"font-weight: 400\">In August 2024, the Union Cabinet, chaired by Prime Minister Narendra Modi, approved the BioE3 Policy. BioE3 stands for Biotechnology for Economy, Environment and Employment. It was prepared by the Department of Biotechnology (DBT) to promote high-performance biomanufacturing, which means producing medicines, materials and chemicals using biological systems instead of traditional chemical methods.<\/span><\/p>\n<p><span style=\"font-weight: 400\">The main objectives of the BioE3 Policy are:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">To speed up India&#8217;s shift from chemical-based industries to sustainable, bio-based models.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">To promote a circular bioeconomy, where waste is turned into useful resources.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">To support India&#8217;s net-zero carbon goals and the Lifestyle for Environment (LiFE) movement.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">To create bio-foundry clusters, biomanufacturing hubs and Bio-AI hubs.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">To generate jobs, especially in tier-II and tier-III cities, where local biomass can be used as raw material.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\">It is worth remembering that BioE3 is not India&#8217;s first biotechnology initiative. Earlier efforts, such as the National Biotechnology Development Strategy and the National Biopharma Mission, had already laid the groundwork. BioE3 builds on them with a strong focus on manufacturing and sustainability.<\/span><\/p>\n<h2><b>Why India Is a Global Biotech Leader<\/b><\/h2>\n<p><span style=\"font-weight: 400\">Several strengths place India at the centre of the global biotechnology sector:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><b>Vaccine capital of the world:<\/b><span style=\"font-weight: 400\"> India produces about 60% of the world&#8217;s vaccines.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Strong manufacturing base:<\/b><span style=\"font-weight: 400\"> India has the second-largest number of USFDA-approved manufacturing plants outside the United States.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Rich biodiversity:<\/b><span style=\"font-weight: 400\"> The country&#8217;s wide range of plants, microbes, and ecosystems offers a valuable base for research and new products.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Skilled talent and low costs:<\/b><span style=\"font-weight: 400\"> A large pool of scientists and engineers makes research and production affordable.<\/span><\/li>\n<\/ul>\n<h2><b>Recent Breakthroughs in Indian Biotechnology<\/b><\/h2>\n<p><span style=\"font-weight: 400\">Indian scientists and companies have achieved several important milestones in recent years:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><b>DNA-based COVID-19 vaccine:<\/b><span style=\"font-weight: 400\"> India developed ZyCoV-D, an indigenous DNA-based vaccine against COVID-19.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>First indigenous HPV vaccine:<\/b><span style=\"font-weight: 400\"> India developed its first indigenously made vaccine against the human papillomavirus, which causes cervical cancer. It is important to note that this is India&#8217;s first indigenous HPV vaccine, not the world&#8217;s first.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Nafithromycin:<\/b><span style=\"font-weight: 400\"> This is India&#8217;s first indigenously discovered antibiotic. It is effective against drug-resistant respiratory infections and is an important step in the fight against antimicrobial resistance.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Gene therapy for haemophilia:<\/b><span style=\"font-weight: 400\"> India&#8217;s first-in-human gene therapy trial for haemophilia was carried out by BRIC-inStem in collaboration with CMC Vellore. Reported results showed a 60 to 70 percent correction rate with no bleeding episodes, a landmark for Indian medical research.<\/span><\/li>\n<\/ul>\n<h2><b>Startups, Institutions and Collaboration<\/b><\/h2>\n<p><span style=\"font-weight: 400\">India now has more than 10,000 biotech startups, compared with only about 50 a decade ago. Many of them work on sustainable products such as bio-based materials, animal-free dairy alternatives and low-cost diagnostics.<\/span><\/p>\n<p><span style=\"font-weight: 400\">The government has also strengthened the ecosystem through several initiatives:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><b>Mission COVID Suraksha:<\/b><span style=\"font-weight: 400\"> During the pandemic, the DBT supported vaccine candidates, clinical trial sites and testing facilities, which improved India&#8217;s own capabilities.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Biotechnology Research and Innovation Council (BRIC):<\/b><span style=\"font-weight: 400\"> This body brings 14 autonomous DBT institutes under one umbrella so that they can work together instead of separately.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Whole-of-science, whole-of-government, whole-of-nation approach:<\/b><span style=\"font-weight: 400\"> Researchers, government departments, universities and industry are encouraged to cooperate.<\/span><\/li>\n<\/ul>\n<h2><b>Other Frontier Technologies<\/b><\/h2>\n<p><span style=\"font-weight: 400\">India&#8217;s ambitions are not limited to biotechnology. The country is investing in other future technologies as well:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><b>National Quantum Mission:<\/b><span style=\"font-weight: 400\"> aims to build strong capabilities in quantum computing, communication and sensing.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Deep Ocean Mission:<\/b><span style=\"font-weight: 400\"> focuses on exploring and using ocean resources in a sustainable way.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Anusandhan National Research Foundation (ANRF):<\/b><span style=\"font-weight: 400\"> created to fund research and bring in strong private sector participation.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Space programme:<\/b><span style=\"font-weight: 400\"> Indian astronaut Group Captain Shubhanshu Shukla travelled to the International Space Station in 2025, showing India&#8217;s growing role in human spaceflight.<\/span><\/li>\n<\/ul>\n<h2><b>Challenges Ahead<\/b><\/h2>\n<p><span style=\"font-weight: 400\">Despite the progress, India must still deal with some challenges. Long-term capital investment is needed for biomanufacturing plants. Clear and quick regulatory approvals are important for new therapies. Cooperation between the Centre and the states must improve, and more skilled workers must be trained in areas such as bioprocessing and bioinformatics. Public trust, ethical standards and biosafety also need constant attention as technologies like gene therapy become more common.<\/span><\/p>\n<h2><b>Quick Facts for Exams<\/b><\/h2>\n<ul>\n<li style=\"font-weight: 400\"><b>BioE3 Policy:<\/b><span style=\"font-weight: 400\"> approved by the Union Cabinet in August 2024; full form is Biotechnology for Economy, Environment and Employment.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Bioeconomy growth:<\/b><span style=\"font-weight: 400\"> about $10 billion in 2014 to over $130 billion in 2024; target of $300 billion by 2030.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Vaccines:<\/b><span style=\"font-weight: 400\"> India produces about 60% of global vaccines.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>BRIC:<\/b><span style=\"font-weight: 400\"> unites 14 autonomous DBT institutes.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Nafithromycin:<\/b><span style=\"font-weight: 400\"> India&#8217;s first indigenously discovered antibiotic.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Gene therapy:<\/b><span style=\"font-weight: 400\"> first-in-human haemophilia trial by BRIC-inStem and CMC Vellore.<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Key minister:<\/b><span style=\"font-weight: 400\"> Dr. Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology.<\/span><\/li>\n<\/ul>\n<h2><b>Conclusion<\/b><\/h2>\n<p><span style=\"font-weight: 400\">India&#8217;s biotechnology revolution shows how innovation and sustainability can move together. With the BioE3 Policy, a growing startup ecosystem, strong vaccine manufacturing and landmark research in gene therapy and antibiotics, India is moving from being a technology taker to a technology maker. If the country keeps investing in research, skilled people and green manufacturing, the biotechnology sector can become a major driver of economic growth, employment and environmental protection on the way to 2047.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>India\u2019s Ascension as a Global Leader in Biotechnology:\u00a0Steering Change for Innovation, Sustainability and Economic Development. Modern India\u2019s fast growth in biotechnology has placed the country at a strategic place of global importance to determine more and more of the future of world technologies, society, and economy, environmental solutions, and innovations. Through visionary leadership, strategic policies, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":26193,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[13],"tags":[],"class_list":["post-24548","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/posts\/24548","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/comments?post=24548"}],"version-history":[{"count":3,"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/posts\/24548\/revisions"}],"predecessor-version":[{"id":28772,"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/posts\/24548\/revisions\/28772"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/media\/26193"}],"wp:attachment":[{"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/media?parent=24548"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/categories?post=24548"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.class24.study\/current-affairs\/wp-json\/wp\/v2\/tags?post=24548"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}